Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain and rash. The ...

Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales. In final guidance ...

Opdivo (nivolumab) is a brand-name drug that’s prescribed for certain types of cancer. Opdivo isn’t known to interact with other medications. Opdivo is prescribed to adults for treating ...

Last week’s NICE rejection of Opdivo for routine use in lung cancer patients has presented BMS with another setback – and an opportunity for Merck Sharp & Dohme (Merck in the US) and its rival ...

Nivolumab (branded as Opdivo) - will be free from 1 November for eligible people with kidney cancer. Director of pharmaceuticals Geraldine MacGibbon said the drug-funding agency was pleased to ...

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo. Opdivo (nivolumab) with Abraxane (nab-paclitaxel) could expand the therapeutic ...

Findings from the CheckMate 067 of patients with advanced melanoma include the longest follow-up of a checkpoint inhibitor in any tumor type. Among patients with advanced melanoma, treatment with ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market ...

The company has a new logo, designed by Pentagram, that looks incredibly plain — especially compared to previous iterations of the logo that featured a rakish slant, two shades of blue ...

under the brand name Opdivo, Kyodo News Agency reported. While it is highly effective in treating multiple types of cancer, ...

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC). These adult patients ...

September saw several notable 'firsts' in the regulatory landscape alongside the approval of four novel drugs in the U.S. Among ...